MAPT and Alzheimer disease: In INTERCEPT-AD, multiple ATX(N) biomarkers (A = Aβ pathway, T = tau-mediated pathophysiology, X = additional pathophysiological mechanisms such as synaptic dysfunction, N = neurodegeneration) [13,14] were measured in CSF and EDTA-plasma as exploratory measures of PD activity [11].